RSSS:NASDAQResearch Solutions, Inc Analysis
Data as of 2026-06-13 - not real-time
$2.33
Latest Price
7/10Risk
Risk Level: Medium
Executive Summary
Technical outlook: RSSS trades at $2.33, below its 20‑day, 50‑day and 200‑day moving averages (2.23, 2.40, 2.81), signaling a bearish price trend. The RSI sits at 51.7, indicating a neutral momentum, while the MACD line has just crossed above its signal line, giving a modest bullish hint. Volume is on a decreasing trajectory and 30‑day volatility is high at 68%, suggesting fragile short‑term price stability. Valuation signals: The forward P/E of ~15.2 is well under the industry average of 36.8, but the DCF‑derived fair value ($2.17) is below the current price, hinting at a slight overvaluation on a cash‑flow basis. The market’s “Extreme Greed” sentiment (fear‑greed index 89.86) may be inflating the price beyond fundamentals.
Fundamental backdrop: Revenue slipped 4.3% YoY to $48.7 M, yet subscription revenue rose 7% and gross margin improved to 51.7%, reflecting better pricing power and cost control. Net income turned positive at $860 k and adjusted EBITDA grew 14%, while ROE is a robust 29.8% and the balance sheet is debt‑free with $12 M cash. ARR expanded 8.5% to $22.1 M, underscoring recurring‑revenue momentum. Despite these strengths, B2B churn remains a drag, and the stock’s upside potential is sizable (target median $4.00, ~70% upside).
Fundamental backdrop: Revenue slipped 4.3% YoY to $48.7 M, yet subscription revenue rose 7% and gross margin improved to 51.7%, reflecting better pricing power and cost control. Net income turned positive at $860 k and adjusted EBITDA grew 14%, while ROE is a robust 29.8% and the balance sheet is debt‑free with $12 M cash. ARR expanded 8.5% to $22.1 M, underscoring recurring‑revenue momentum. Despite these strengths, B2B churn remains a drag, and the stock’s upside potential is sizable (target median $4.00, ~70% upside).
Market Outlook
Short Term
< 1 yearNeutral
Model confidence: 5/10
Key Factors
- Price below all major moving averages
- Decreasing volume and high short‑term volatility
- Neutral RSI and modest MACD bullish crossover
Medium Term
1–3 yearsPositive
Model confidence: 7/10
Key Factors
- Strong margin expansion and positive EBITDA growth
- ARR increase of 8.5% and subscription revenue up 7%
- Undervalued relative to industry P/E and sizable upside to target price
Long Term
> 3 yearsPositive
Model confidence: 8/10
Key Factors
- High ROE (~30%) and debt‑free balance sheet
- Growing recurring‑revenue base and AI‑enhanced product roadmap
- Long‑term upside potential despite current revenue contraction
Key Metrics & Analysis
Financial Health
Revenue Growth-4.30%
Profit Margin9.28%
P/E Ratio15.5
ROE29.82%
ROA5.42%
P/B Ratio4.3
Op. Cash Flow$5.8M
Free Cash Flow$4.6M
Industry P/E36.8
Technical Analysis
TrendBearish
RSI51.7
Support$2.00
Resistance$2.45
MA 20$2.23
MA 50$2.40
MA 200$2.81
MACDBullish
VolumeDecreasing
Fear & Greed Index89.86
Valuation
Fair Value$2.17
Target Price$3.83
Upside/Downside64.52%
GradeFair
TypeBlend
Risk Assessment
Beta0.71
Volatility68.07%
Sector RiskMedium
Reg. RiskLow
Geo RiskLow
Currency RiskLow
Liquidity RiskMedium
Similar Tickers
This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.